Overview

First Line TIP in Poor Prognosis TGCTs.

Status:
Completed

Trial end date:
2020-06-01

Target enrollment:

Participant gender:

Summary

TIP in the 1st line treatment of GCTs patients with unfavorable decline of serum tumor markers after 1 cycle of the BEP regimen.TIP will be administered to the patient until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute, Slovakia

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Ifosfamide
Isophosphamide mustard
Paclitaxel